No Data
Accelerating recovery? In March, domestic Innovative Drugs investment and financing increased by about 50% year-on-year, and the Hong Kong Stock pharmaceutical Sector collectively surged.
① In March, domestic investment and financing for Innovative Drugs increased by approximately fifty percent year-on-year, how significant is the Bullish impact? ② The Hong Kong stock market's pharmaceutical Sector rose collectively, which stocks are attracting market attention?
Wuxi Biologics' Growth Trajectory Stable But Tariff Risks Linger -- Market Talk
WUXI BIO (02269) issued 4.1654 million shares due to the exercise of Options.
WUXI BIO (02269) announced that from April 14 to April 23, 2025, due to the exercise of Options...
WUXI BIO has been rated as a leader in climate change by CDP for two consecutive years.
- Firmly implement commitments to combat climate change and actively respond to the United Nations Sustainable Development Goals. - Actively support the annual initiative of "Earth Day" — Action with you, Strength for the Earth, co-creating a sustainable development paradigm. Shanghai, April 22, 2025 /PR Newswire/ -- WUXI BIO, a global leading contract research, development, and manufacturing (CRDMO) service company, announced that it has received high recognition from the global environmental non-profit organization CDP for its outstanding performance and transparent disclosure in addressing climate change, achieving an A- rating for two consecutive years.
WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year
Trending Industry Today: INNOCARE Leads Gains In Biotechnology Stocks
投机的阿妍 : The USA business has been sold, now is the time to buy at a discount.